- Home
- AOMR vs TLSA Comparison
AOMR vs TLSA Comparison
Compare AOMR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- TLSA
- Stock Information
- Founded
- AOMR 2018
- TLSA 2013
- Country
- AOMR United States
- TLSA United Kingdom
- Employees
- AOMR N/A
- TLSA N/A
- Industry
- AOMR Real Estate Investment Trusts
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- TLSA Health Care
- Exchange
- AOMR Nasdaq
- TLSA Nasdaq
- Market Cap
- AOMR 211.5M
- TLSA 187.0M
- IPO Year
- AOMR 2021
- TLSA 2000
- Fundamental
- Price
- AOMR $9.84
- TLSA $1.79
- Analyst Decision
- AOMR Strong Buy
- TLSA
- Analyst Count
- AOMR 6
- TLSA 0
- Target Price
- AOMR $11.25
- TLSA N/A
- AVG Volume (30 Days)
- AOMR 225.2K
- TLSA 378.1K
- Earning Date
- AOMR 08-05-2025
- TLSA 05-06-2025
- Dividend Yield
- AOMR 12.98%
- TLSA N/A
- EPS Growth
- AOMR N/A
- TLSA N/A
- EPS
- AOMR 1.56
- TLSA N/A
- Revenue
- AOMR $57,661,000.00
- TLSA N/A
- Revenue This Year
- AOMR N/A
- TLSA N/A
- Revenue Next Year
- AOMR $13.75
- TLSA N/A
- P/E Ratio
- AOMR $6.31
- TLSA N/A
- Revenue Growth
- AOMR N/A
- TLSA N/A
- 52 Week Low
- AOMR $7.36
- TLSA $0.63
- 52 Week High
- AOMR $11.51
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- AOMR 57.41
- TLSA 45.34
- Support Level
- AOMR $9.61
- TLSA $1.73
- Resistance Level
- AOMR $9.81
- TLSA $2.00
- Average True Range (ATR)
- AOMR 0.20
- TLSA 0.16
- MACD
- AOMR 0.02
- TLSA -0.04
- Stochastic Oscillator
- AOMR 78.31
- TLSA 13.35
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.